Abstract: The present invention provides systems and methods for rapid screening of individuals who may have been exposed to and carrying biological agents potentially contagious or otherwise harmful to the general public.

Abstract: Compositions and methods for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number. Described herein is a method that entails assaying a sample obtained from the urogenital tract of the mammal for an indicator of genomic copy number, wherein a genomic copy number level that is higher than a control genomic copy number level is indicative of the presence of infection or inflammation of the urogenital tract.

Abstract: The present invention provides systems and methods for rapid screening of individuals who may have been exposed to and carrying biological agents potentially contagious or otherwise harmful to the general public.

Abstract: Compositions and methods for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number. Described herein is a method that entails assaying a sample obtained from the urogenital tract of the mammal for an indicator of genomic copy number, wherein a genomic copy number level that is higher than a control genomic copy number level is indicative of the presence of infection or inflammation of the urogenital tract.

Abstract: Compositions and methods for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number. Described herein is a method that entails assaying a sample obtained from the urogenital tract of the mammal for an indicator of genomic copy number, wherein a genomic copy number level that is higher than a control genomic copy number level is indicative of the presence of infection or inflammation of the urogenital tract.

Abstract: A fluid pump includes a primary impeller and a secondary impeller disposed on a common drive shaft within a pump housing. The pump housing including a respective diffuser or volute therein for each of the primary impeller and the secondary impeller. A fluid passage is formed within the housing connecting a discharge of the primary impeller to an intake of the secondary impeller. Each of the primary and secondary impellers has a respective outlet port.

Abstract: A fluid pump includes a primary impeller and a secondary impeller disposed on a common drive shaft within a pump housing. The pump housing including a respective diffuser or volute therein for each of the primary impeller and the secondary impeller. A fluid passage is formed within the housing connecting a discharge of the primary impeller to an intake of the secondary impeller. Each of the primary and secondary impellers has a respective outlet port.

Abstract: A method for classifying cancer patients as likely to have lower response to MET receptor antagonist therapy comprises assessment of the presence or absence of a single nucleotide polymorphism in the MET promoter in a patient tissue sample. The invention provides more effective identification of patients to receive MET receptor antagonist therapy.

Abstract: A method for classifying cancer patients as eligible to receive cancer therapy with a small molecule inhibitor of Bcl-2 comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number status at the chromosomal locus 13q14 comprising the microRNA's miR15a and miR16-1. The classification of cancer patients based upon the presence or absence of 13q14 loss or gain allows better selection of patients to receive chemotherapy with a small molecule Bcl-2 inhibitor such as N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1- yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- ((trifluoromethyl)sulfonyl)benzenesulfonamide, and for monitoring patient response to this therapy.

Abstract: A method for classifying cancer patients as eligible to receive cancer therapy with a small molecule inhibitor of Bcl-2 comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number status at the chromosomal locus 13q14 comprising the microRNA's miR-15a and miR-16-1 or at the chromosomal locus 11q23.1 comprising the microRNA miR-34c. The classification of cancer patients based upon the presence or absence of 13q14 loss or gain allows better selection of patients to receive chemotherapy with a small molecule Bcl-2 inhibitor such as N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, and for monitoring patient response to this therapy.

Abstract: A method for classifying cancer patients as likely to have lower response to MET receptor antagonist therapy comprises assessment of the presence or absence of a single nucleotide polymorphism in the MET promoter in a patient tissue sample. The invention provides more effective identification of patients to receive MET receptor antagonist therapy.

Abstract: A centrifugal pump assembly and method of using same including a vertical or horizontal overhung housing assembly having a primary inlet, a primary discharge, a secondary inlet and a secondary discharge. A shaft is in spaced relationship within the overhung housing assembly. A single primary impeller is mounted on the shaft for receiving fluid from the primary inlet and discharging fluid through the primary discharge. A booster impeller is mounted on the shaft and juxtaposed the main impeller for receiving fluid from the secondary inlet and discharging fluid through the secondary discharge. All fluid introduced to the secondary inlet originates from the primary discharge or may be diverted from the fluid flow upstream of the centrifugal pump assembly or the primary impeller. The fluid in the secondary inlet flows through the booster impeller and discharges through the secondary discharge. The secondary discharge is separate from the primary discharge.